小分子GLP-1RA 发展前景广阔,近年来重磅BD 交易频发小分子GLP-1RA 具有成本低、使用场景不受限、无需冷链运输等诸多优势,发展前景广阔。针对小分子GLP-1RA 赛道,礼来的Orforglipron 已完成降糖与肥胖的全球III 期,保持全球领先的地位;AZ 的AZD5004、罗氏的CT-996、礼来的NAPERIGLIPRON 与Terns 的TERN-601 已进入II 期,整体...
Source Link小分子GLP-1RA 发展前景广阔,近年来重磅BD 交易频发小分子GLP-1RA 具有成本低、使用场景不受限、无需冷链运输等诸多优势,发展前景广阔。针对小分子GLP-1RA 赛道,礼来的Orforglipron 已完成降糖与肥胖的全球III 期,保持全球领先的地位;AZ 的AZD5004、罗氏的CT-996、礼来的NAPERIGLIPRON 与Terns 的TERN-601 已进入II 期,整体...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.